Sorrento has lots of Covid-19 exposure, but it might be too much as reflected by recent weakness in SRNE stock.

The company does appear to be stretched. But there are still advantages for SRNE stock that make it interesting to investors.

There are several established biotech companies for investors to consider but they should avoid buying SRNE stock.

While Sorrento Therapeutics has an impressive pipeline, it needs to bring something to market. The clock is ticking on SRNE stock.

Sorrento has a ton of interesting clinical work going on. But with Covid-19 science rapidly advancing, SRNE stock doesn't have much time left to cash in.

If you love to gamble, SRNE stock is the right one for you. Few other companies, if any, have pivoted as hard as Sorrento did toward Covid-19. Just be aware of the risks.

After running up more than 1,000% this year, Sorrento Therapeutic's stock has pulled back with the broader market in September and is now down 43% from its peak. This retrenchment has spooked many investors. However, patient investors who are willing to stick with Sorrento, or those who buy at the current price, may be rewarded with big future returns.

SRNE stock is up over 200% because the company is taking several bites at the Covid-19 apple. However time is not on the company's side.

So, what's the call here? If you have a high risk tolerance, and are looking for a short-term pandemic play, SRNE stock today may be worth the risk. Just don't bet the ranch.

Sorrento has some potential positive catalysts, especially its Covid-19 diagnostic test. But SRNE stock is really just for the speculative part of your portfolio.